Verona Emerges Victorious From Second COPD Trial
Ensifentrine Will Head To FDA In First Half Of 2023
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
You may also be interested in...
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.